Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:DSNKY

Daiichi Sankyo 1/31/2025 Earnings Report

Daiichi Sankyo logo
$18.71 +0.43 (+2.35%)
As of 03:12 PM Eastern
ProfileEarnings HistoryForecast

Daiichi Sankyo EPS Results

Actual EPS
$0.22
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Daiichi Sankyo Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Daiichi Sankyo Announcement Details

Quarter
Date
1/31/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Daiichi Sankyo's next earnings date is estimated for Friday, October 30, 2026, based on past reporting schedules.

Conference Call Resources

Daiichi Sankyo Earnings Headlines

Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up After Analyst Upgrade
September 24 at 5:32 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044438
Astra-Daiichi breast cancer drug Enhertu recommended for NHS use in England
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/astra-daiichi-breast-cancer-drug-enhertu-recommended-for-nhs-use-in-england/ar-AA2crf58
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
September 25 at 1:00 AM  |  Paradigm Press (Ad)
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk
August 28, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260828631780/en/new-daiichi-sankyo-data-underscore-the-effect-of-bempedoic-acid-in-the-real-world-management-of-dyslipidemia-and-cardiovascular-risk/
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
August 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260821102599/en/daiichi-sankyo-appoints-markus-kosch-to-lead-europe-business-as-part-of-new-commercialization-organization/
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
August 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260823786995/en/daiichi-sankyo-appoints-ken-keller-as-chief-commercialization-officer-to-lead-new-commercialization-unit-to-accelerate-growth-of-innovative-portfolio/
See More Daiichi Sankyo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email.

About Daiichi Sankyo

Daiichi Sankyo (OTCMKTS:DSNKY) Co., Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies. Its broader portfolio includes Lixiana, also known as Savaysa in some markets, an oral anticoagulant based on edoxaban.

Daiichi Sankyo was formed in 2005 through the merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd., two established Japanese drugmakers. The company is headquartered in Tokyo and serves markets in Japan, North America, Europe and other international regions through its global research, manufacturing and commercial operations.

View Daiichi Sankyo Profile
Earnings Tools